Rahul Dhanda, Syntis Bio CEO

New obe­si­ty biotech Syn­tis Bio launch­es with ear­ly-stage al­ter­na­tive to GLP-1s

Syn­tis Bio is join­ing a grow­ing group of small­er com­pa­nies that are mov­ing in­to the obe­si­ty treat­ment space — but not with a GLP-1.

In­stead, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.